AFT.NZ
AFT Pharmaceuticals LimitedExplain this page
Arphra AIPlain-English read on AFT Pharmaceuticals Limited’s valuationRatios & metrics
Profitability, returns on capital, growth, and credit — all derived from the historical income statement, balance sheet, and cash flow rows in our data warehouse.
A snapshot of the latest fiscal year’s margins, returns on capital, balance-sheet strength and efficiency, computed from the income statement, balance sheet and cash-flow rows. Source income / balance / cash_flow.
Valuation multiples
| In USD | FY 2026 |
|---|---|
| Headline | |
| Market cap | $352.35M |
| Enterprise value | $396.22M |
| Multiples | |
| P / E | — |
| P / B | — |
| EV / EBITDA | — |
| EV / Sales | 1.56 |
| EV / FCF | -33.39 |
| Yields | |
| Earnings yield | +4.18% |
| Free cash flow yield | -3.37% |
| Dividend yield | — |
Profitability
| In USD | FY 2026 |
|---|---|
| Margins | |
| Gross margin | +43.40% |
| Operating margin | +9.76% |
| EBITDA margin | +11.21% |
| EBIT margin | +9.76% |
| Pre-tax margin | +8.59% |
| Net margin | +5.78% |
| Cost structure | |
| Cost of revenue / sales | +56.60% |
| R&D intensity | +4.35% |
| SG&A intensity | +29.30% |
| Effective tax rate | +35.64% |
Returns on capital
| In USD | FY 2026 |
|---|---|
| Returns | |
| Return on equity (ROE) | +13.51% |
| Return on assets (ROA) | +6.79% |
| Return on capital (ROC) | +15.23% |
| Return on invested capital (ROIC) | +9.03% |
| Asset turnover | +117.37% |
| DuPont · ROE decomposition | |
| Net margin | +5.78% |
| Asset turnover (× revenue / assets) | +117.37% |
| Equity multiplier (× assets / equity) | +198.97% |
Activity & efficiency
| In USD | FY 2026 |
|---|---|
| Turnover | |
| Asset turnover | 1.17 |
| Fixed-asset turnover | 75.76 |
| Inventory turnover | 1.95 |
| Receivables turnover | 3.97 |
| Payables turnover | 4.87 |
| Days outstanding | |
| Days sales outstanding (DSO) | 92.05 |
| Days inventory outstanding (DIO) | 187.54 |
| Days payables outstanding (DPO) | 74.93 |
| Cash conversion cycle | 204.66 |
Cash flow quality
| In USD | FY 2026 |
|---|---|
| Operating CF / Net income | -0.80 |
| FCF / Net income | -0.81 |
| FCF margin | -4.66% |
| OCF margin | -4.61% |
| CapEx / Revenue | +0.05% |
| CapEx / D&A | 0.03 |
| Stock-based comp / Revenue | 0.00% |
Per-share & shareholder yield
| In USD | FY 2026 |
|---|---|
| EPS · diluted | 0.14 |
| EPS · basic | 0.14 |
| Book value / share | 1.04 |
| Tangible BV / share | 0.43 |
| Sales / share | 2.43 |
| Operating CF / share | -0.11 |
| Free cash flow / share | -0.11 |
| Dividends / share | 0.02 |
| Payout ratio | +12.81% |
| Retention ratio | +87.19% |
Growth
| In USD | FY 2026 | CAGR |
|---|---|---|
| Top-line | ||
| Revenue · YoY | — | — |
| Gross profit · YoY | — | — |
| Profit | ||
| Operating income · YoY | — | — |
| EBITDA · YoY | — | — |
| Net income · YoY | — | — |
| Operating | ||
| EBIT · YoY | — | — |
| R&D · YoY | — | — |
| Per-share | ||
| EPS · diluted · YoY | — | — |
| EPS · basic · YoY | — | — |
Credit & leverage
| In USD | FY 2026 |
|---|---|
| Leverage | |
| Total debt | $54.11M |
| Net debt | $43.87M |
| Net debt / EBITDA | 1.54 |
| Debt / equity | 0.50 |
| Debt / assets | +24.93% |
| Equity / assets | +50.26% |
| Coverage | |
| EBITDA / interest expense | 11.47 |
| Operating income / interest | 9.98 |
| Interest expense | $2.49M |
| Liquidity | |
| Current ratio | 2.24 |
| Quick ratio | 1.12 |
| Cash ratio | 0.15 |
| Working capital | $82.2M |
| Working capital / revenue | +32.27% |
Historical multiples · μ ± σ bands
3 fiscal-year-end observations from key_metrics. Mean is dashed; light-green band is ±1σ, light-red band ±2σ. The dot marks the most recent value; the cheap / fair / rich verdict uses z-score against the issuer's own history (yields inverted — a high yield is cheap).
Sourced from key_metrics + financial_ratios (loaded by load_fundamentals_extended.py).
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| P / E | — | — | — |
| P / B | — | — | — |
| EV / EBITDA | — | — | — |
| EV / Sales | 1.56x | 1.46x | 1.77x |
| Earnings yield | 4.2% | 4.2% | 4.8% |
| FCF yield | -3.4% | 2.2% | 4.9% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| ROE | 13.4% | 12.3% | 17.8% |
| ROA | 6.8% | 7.0% | 9.4% |
| ROIC | 9.8% | 6.5% | 14.3% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / equity | — | — | — |
| Net debt / EBITDA | 1.54 | 0.88 | 0.73 |
| Interest coverage | — | — | — |
| Current ratio | 2.24x | 2.50x | 2.30x |
| Quick ratio | — | — | — |
Methodology. ROE / ROA / ROC use period-end balance-sheet denominators (no average-of- period smoothing). ROIC = Operating Income × (1 − inferred effective tax rate) over invested capital, with the effective tax inferred from net-to-operating income when both are positive and a 25% default otherwise. Net debt / EBITDA, debt ratios, and interest-coverage ratios are calculated point-in-time at each fiscal year-end. TTM = trailing 4 quarters (income / cash flow summed, balance sheet = most-recent quarterly snapshot). Through-cycle CAGR in the Growth panel uses the geometric mean of first-to-last period growth across the window (positive values only).